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Abstract
Background: Considerable interest has been shown by athletes and scientists in the potential for nitric oxide and 
associated vasodilators to enhance performance. This study aims to explore potential misuse of vasodilators by the 
athletes, and to highlight the growing concern over these agents.
Methods: Retrospective analyses of anonymous inquiries recorded in the Drug Information Database™ (DID™) 
between January 2006 and June 2008 (inclusive). In this 30-month period, the DID™ recorded 198,023 inquiries, of 
which 118,724 were UK Licensed Pharmaceutical products with a further 79,299 inquiries made for substance not 
found in the database.
Results: Phosphodiesterase type 5 (PDE-5) inhibitors, dominated by Viagra®, ranked 16th among the substance groups. 
The proportion of the inquiries made regarding PDE-5 inhibitors, especially in comparison to antibiotics, painkillers or 
alcohol, appears to be above the level that would normally be expected from medical need. No significant change in 
the months leading up to the Beijing Olympics was observed. On the contrary, the Nitric/Nitrate group showed a 
notable increase between 2006-2007 and 2008, suggesting a potential increase in interest in using nitric oxide among 
athletes.
Conclusions: With patents recently filed for the use of agents containing sodium nitrite/nitrate to enhance blood flow 
for performance enhancement in sport, coupled with anecdotal evidence from internet athlete forums and media, 
there is a concern that athletes may endanger their health by using vasodilators to enhance athletic performance. PDE-
5 inhibitors or chemicals in the nitrate/nitrate group are currently not prohibited or tested for by the doping control 
agencies but some are highly dangerous to health and can lead to cardiovascular collapse, coma and death. Its 
promotion among athletes as a performance enhancing supplement is ethically and medically questionable.
Introduction
The discovery of the vasodilator role of nitric oxide (NO·)
has led to a revolution in pharmacology over the past two
decades which has brought considerable innovations in
NO·-related therapy. Apart from helping to elucidate the
mode of action of well established treatments such as
nitroglycerine, the contribution of advances in NO·
research have mainly exerted an effect in the clinic
through advances in the understanding and application of
nitrite, a precursor to NO·. Just over a decade ago, the
efficiency of NO· production by the metallo-enzyme xan-
thine oxidoreductase was demonstrated [1]. In vitro and
under hypoxia, this enzyme is considerably more effec-
tive than nitric oxide synthase at generating NO· [1].
More recently, this phenomenon was observed for deoxy-
haemoglobin [2], leading to the recent demonstration
that nitrite has considerable protective effects in a range
of cardiovascular conditions, including myocardial
infarctions [3]. Nitrite, currently licensed for the treat-
ment of cyanide toxicity, will undoubtedly continue to
make a major clinical impact unless a serious side effect
emerges. The long term benefits and risks of nitrite ther-
apy have yet to be elucidated although Martindale: The
Extra Pharmacopoeia lists the serious side effects as con-
vulsions, cardiovascular collapse, coma and death.
Participants in professional sports can exhibit adept
abilities to take advantage of advances in medicine relat-
ing to performance enhancement. It is not surprising that
many athletes have looked at vasodilators to embellish
their performances on the playing field. Reports of reli-
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Page 2 of 7ance on vasodilator drugs used for sexual dysfunction are
common, even at the national team level. One report
identifies the distributions of Viagra® to a national soccer
team playing at high altitude, supposedly without the
players' knowledge [4]. This use has also been recognised
by sport governing bodies as the World Anti Doping
Agency (WADA) currently sponsor a study of the perfor-
mance enhancing effects of sildenafil (Viagra®) at mild
altitude [5].
With the advent of easy availability of drugs and supple-
ments via the internet, along with numerous unregulated
discussion sites, it is concerning that athletes may
unknowingly transgress from using harmless supple-
ments to prescription only medicines in the absence of
clinical supervision (Figure 1). The requirement for clini-
cal supervision is reflected by the serious side effect pro-
files that are associated with these drugs. Our previous
research shows that a concerning lack of understanding
in supplements and their effect exist even among high-
performing athletes who benefit from readily available
support from nutritionists, doctors and physiotherapists
[6-8]. Furthermore it has been shown that those who use
supplements tend to use more than one concomitantly
[8-12], including different types [13-15] and may move
from one category to the next more effective substance
[16-18]. As shown in Figure 1, various categories of sub-
stances willingly ingested by athletes and physically active
people cannot be appropriately evaluated in isolation.
One approach to gauging the interests of athletes in
vasodilators is to analyse inquiries lodged with the Drug
Information Database™ (DID™). The DID™ was developed
and hosted by elite sport© and launched in the UK via UK
Sport in 2002 and provided a self-check tool for athletes
and support personnel (coaches, doctors, pharmacists,
teachers, parents) until 2009. The anonymous inquiries
were recorded since January 2006, cataloguing some
9,000 inquiries each month, predominantly from athletes
themselves. The database contained UK licensed phar-
maceutical products and was searchable by trade names
and active ingredients, and linked to the current List of
Prohibited substances published by the WADA [19].
Information returned on the individual inquiries
included in- and out-of competition status of the drug,
including differentiation by the route of administration.
The inquiries recorded via the DID™ have been scruti-
nized and shown to be a reflection of athletes' practices
[20]. Beyond and above the evidence reported by Petroczi
& Naughton [20], the validity of the database was further
checked by mapping the trend in inquiries made about
antihistamines and the onset of common pollen allergies
(trees, grass and weeds). The close match between the
inquiries and the seasonal variations in pollen allergies
(data not shown) provided further reassurance for the
validity.
This report presents an analysis of inquiries made on
vasodilators to the DID™ during 2006-2008, leading up to
the Beijing Olympics. It covers inquiries relating to i) pre-
scription only phosphodiesterase inhibitors and ii) nitric
oxide precursor supplement products. A key distinction
between these two classes of vasodilator is their legal sta-
tus with the former having been the subject of exhaustive
clinical trials while the latter have been less well docu-
mented in terms of effects on human health. A further
distinction is that the official standing of the prescription
medicines affords the ability to study their use which is
unavailable for the grey area of "nitric oxide precursor"
supplement use. Additionally, it should be noted that the
second class is comprised of supplement products of var-
ious compositions. Some of these are nitrogen-containing
products that take advantage of the nitric oxide synthase
pathway to form NO. Other compositions contain
nitrites/nitrates (e.g., there is patent protection for a sup-
plement agent containing sodium nitrite [21]). The differ-
ences within this class may not be apparent to many
consumers, but the ingredients may have significantly dif-
ferent health or detrimental effects (Figure 2). Reports
suggesting the use of prescription vasodilators to enhance
athletic performance by professional athletes [4], may
lead to an increased interest in prescription vasodilators
in the sub-elite level of athletes leading to wider public
health concerns. Furthermore, use of prescription vasodi-
lators, whether obtained by prescription or not, may lead
to the adoption of non-prescription nitrite supplements.
For these reasons, it is timely to study the observed inter-
est in these distinct classes of vasodilators in order to
compare and contrast trends in interest by athletes. A key
aim is to investigate fluctuations in the numbers of que-
ries in each category, to establish if concerning trends inFigure 1 Classes of drugs based on legal status.
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year period leading up to the Olympics.
Methods
The UK Sport's Drug Information Database (DID™) has
been previously interrogated to gain an insight into what
substances athletes and their support personnel are inter-
ested in [20]. In order to elucidate the potential use or
misuse of vasodilators, data previously downloaded from
the DID™ were re-analysed. The data, limited to inquiries
made in the UK, were downloaded in July 2008 in two
segments:
• Dataset 1: Time covering between January 1, 2006, 
and December 31, 2007.
• Dataset 2: Six sets of 2008, in monthly segments, to 
monitor any changes during the months leading up to 
the 2008 Beijing Olympic Games. Comparing to pre-
vious analysis including all inquiries [20] and based 
on 2006-2007 (24 month period) statistics, enquires 
made in the UK formed the majority of the records 
(75% of "found" and 68.5% of "not found").
The present investigation focused on two major sub-
stance categories: Phosphodiesterase type 5 (PDE-5)
inhibitors and the Nitric/Nitrate group. Keywords used
to filter the data included both active ingredients and
brand names (Table 1), but also included clearly identifi-
able word or phrase segments. Owing to widespread use
of internet searches, we included drugs/brands that are
not licensed in the UK. As the inquiries registered in the
DID™ are recorded in two sets, those inquiries that relate
to a drug or substance recognised by the DID™ ("found")
and those that are "not found" [20], both sets were used.
Statistical analyses were conducted using Excel XP® ver-
sion.
In order to create meaningful groups of substances for
further analysis, the recorded inquiries were ranked in
decreasing order and individual contributions to the
complete dataset were calculated and expressed as per-
centages. Previous analysis has shown that the number of
inquiries recorded for each substance decreases exponen-
tially with records greater than 200 yielding meaningful
information [20]. A total of 45 substances received the
highest number of enquires (> 300 for each substance),
which individually account for at least 0.25% of the entire
database. These popular substances were the focus of the
analyses conducted for this report. Less popular formula-
tions of these substances in the remainder of the database
were also included. Queries about substances that match
the database contents are listed as "found" whereas those
that have no match are labelled as "not found". The latter
category include those queries that were mistyped or do
not correspond to a substance in the database. Thus, the
"not found" category can provide information on emerg-
ing substances/names.
Results and Discussion
The combined data (January 2006 to June 2008) contain
118,724 inquiries in the "found" dataset with the highest
one being Lemsip preparations with 3,006 records
(2.53%), followed by caffeine (2,045, 1.72%), ibuprofen
(1709, 1.44%), paracetamol (1,648, 1.39%), ephedrine
(1,440, 1.21%), and salbutamol containing preparations
(1,235, 1.04%). Viagra® was among the top 50 inquiries
with 338 inquiries (0.28%). When combining all PDE-5
inhibitors, before grouping, there were 484 (0.41%) inqui-
ries (equating to 25th place) within this 30-month period.
Queries relating to substances with similar functions,
such as stimulants or painkillers, can be grouped for clar-
ity. The results were categorized by their main function
and ranked as shown in Figure 3 for major categories.
These categories equate to some 30% of all inquiries
made. The breakdown was in the order: stimulants
(4.5%); OTC fever and pain treatments (3.4%); allergy/
anti-histamines (2.6%), for all queries made. Numbers of
inquiries about PDE-5 inhibitors were on par with those
about antibiotics, painkillers and alcohol. Given the pop-
ulation (young athletes), the proportion of interest in
PDE-5 inhibitors appears to be above the level that would
normally be expected for medical reasons. The main
medical reason for such drugs, erectile dysfunction, in
men below 40 years of age is very low (< 3%) [22] and only
increases with chronic medical conditions (e.g. diabetes,
severe obesity) or tobacco smoking - none of which is
expected to be prevalent in the highly trained, competi-
tive athlete group.
As shown in Figure 4, the total number of enquires
about Viagra® type substances per month is comparable
between the two year period to 2008 and during the first
six months of 2008. Among queries that match the data-
base (i.e. "found") small shifts in numbers are seen in the
Figure 2 Categories of nitric oxide-related compositions based 
on mechanism of action.
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ute losses against their brand names Viagra® and Cialis®. A
group of compounds identified as nitric oxide precursors
were identified and monitored. These include (organic)
nitrates, nitric, nitric oxide, NO2® or NO-Xplode®. NO2®
appears on supplement distributor and bodybuilding web
sites and is described as nitrite. In contrast, for nitric
oxide related searches a three-fold increase in queries was
observed despite the absence of these names on the data-
base. In trends: the monthly average for the nitric/nitrate
groups has steadily increased from 2.6% (2006) to 4.6%
(2007) to 6.5% (2008). Thus, there has been a growing
interest in nitrite related agents in contrast to a stable
number of inquiries regarding Viagra® type agents leading
up to the Beijing Olympics.
Evidence from queries made to the DID™ along with
sports internet discussion boards identifies a growing
interest in blood enhancing agents including Viagra® and
nitric oxide based agents. A particular concern is the pro-
motion of these drugs among athletes as performance
enhancing supplements. Many athletes will be unaware of
the potency and side effects associated with their abuse.
In particular, sodium nitrite, the nitric oxide precursor,
has led to fatalities. In a recent event, sodium nitrite was
Table 1: Keywords used for analysing the DID™ data
Category Dataset Keywords
PDE-5 inhibitors "Found" Acetildenafil, Lodenafil (Helleva®), Microdenafil, Sildenafil citrate (Viagra®, Revatio®), Tadalafil 
(Cialis®, Adcirca®), Thiomethisosildenafil, Udenafil (Zydena®) Vardenafil (Levitra®, Vivanza®)
Nitrite/Nitrate "Not Found" Nitric oxide, Nitrate, Nitrix, NO2®, NO-Xplode®
Figure 3 Number of inquires grouped by class between January 2006-June 2008.
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Figure 4 Number of vasodilator related queries during 2006-2008 by category as A) "found" and B) "not found".
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two reported coma cases and four deaths [23], which
highlights the toxicity at small doses that can occur out-
side of clinical supervision.
Many of the supplement products do not contain
sodium nitrite, and it is not suggested here that the prod-
ucts on the market are themselves dangerous. However,
agents to enhance blood flow for performance enhance-
ment in sport have been subject to patent protection and
in one case, the composition contains the active agents as
sodium nitrite/nitrate [21]. The possibility that use of the
other supplement products may lead to the use of danger-
ous products is the primary concern. Clearly, the clinical
applications of nitrite are immense despite the potential
drawbacks of, yet to be fully explored, therapeutic win-
dows [3]. Recent reports of nitrite induced cardiovascular
protection, based on proteome changes [24], have yet to
be ascribed a mechanism. However, it is clear that oxida-
tive damage occurs, as shown by the authors, which may
elicit the protective effects leading to questions regarding
long term use [24]. In recent years, there has been spread-
ing speculation regarding the potential misuse of vasodi-
lators by the athletic population [25]. PDE-5 inhibitors
are currently not prohibited by the WADA but the agency
has funded research to investigate the performance-
enhancing potential of sildenafil [12].
Nitrite/Nitrate and related products are not on the
WADA prohibited list of chemicals either; and as an
endogenous species and component of foodstuffs a regu-
latory test is unlikely. From our current knowledge of
doping reports, athletes are willing to use non-prohibited
and OTC medications to boost their athletic performance
[10-12]. It is concerning that these products frequently
fall outside of medical supervision. Thus, a more accept-
able policy is warranted, along with public awareness ini-
tiatives.
Conclusions
This report demonstrates that, in contrast to interest in
prescription vasodilators, athletes exhibited an increasing
interest in "nitric-oxide precursor" vasodilators as
observed in the DID™ records. There was a marked
increase in inquiries made about these supplements lead-
ing up to the Beijing Olympics. Without medical supervi-
sion, use of vasodilators, especially (sodium) nitrite is
potentially very serious and the adverse effects should be
publicised.
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